Ozempic, Wegovy May Help Reduce Kidney Disease Risk - Healthline
WEBMay 25, 2024 · The findings, which were presented at the 61st ERA Congress Friday, suggest that receiving a weekly injection of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, may help...
Summary of Glucagon-like Peptide-1 Receptor Agonists for Adults
WEBJun 29, 2023 · Glucagon-like peptide-1 (GLP-1) receptor agonists are approved by the Food and Drug Administration for treatment of type 2 diabetes mellitus and cardiovascular risk reduction in this cohort (see table). 1 In addition, GLP-1 …
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R …
WEBDec 1, 2023 · NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced topline data from the Phase 2b clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes.
FDA approves first oral GLP-1 treatment for type 2 diabetes
WEBRybelsus is the first glucagon-like peptide (GLP-1) receptor protein treatment approved for use in the United States that does not need to be injected.
Knowledge gap and prescribing patterns of glucagon-like peptide-1 ...
WEBAug 7, 2024 · Recently, some new anti-diabetic medications, such as glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 (SGLT2) inhibitors have been proven for reduction of...
Metabolic Messengers: glucagon-like peptide 1 - Nature
WEBJan 11, 2021 · Glucagon like peptide-1 (GLP-1), a peptide hormone from the intestinal tract, plays a central role in the coordination of postprandial glucose homeostasis through actions on insulin...
Glucagon-like peptide-1 receptor agonists: What to know
WEBJun 22, 2020 · Glucagon-like peptide-1 receptor agonists (GLP-1 agonists) are one option. In this article, Dr. Maria Prelipcean explains how GLP-1 agonists work, their benefits and risks, and some common...
GLP-1 receptor agonists: an updated review of head-to-head …
WEBMar 9, 2021 · Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are attractive options for the treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while having a low risk of hypoglycemia.
Recent advances in understanding the role of glucagon-like peptide 1
WEBApr 6, 2020 · The discovery that glucagon-like peptide 1 (GLP-1) mediates a significant proportion of the incretin effect during the postprandial period and the subsequent observation that GLP-1 bioactivity is retained in type 2 diabetes (T2D) led to new therapeutic strategies being developed for T2D treatment based on GLP-1 action.
Glucagon-like peptide 1 (GLP-1) - PubMed
WEBGLP-1 also has cardio- and neuroprotective effects, decreases inflammation and apoptosis, and has implications for learning and memory, reward behavior, and palatability.